Cargando…
Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
This study aimed to explore the clinical adverse effects of anthracyclines on patients undergoing chemotherapy after breast cancer surgery. A total of 118 patients who received anthracycline chemotherapy after breast cancer surgery were selected as the research object, and the changes of echocardiog...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380491/ https://www.ncbi.nlm.nih.gov/pubmed/35379700 http://dx.doi.org/10.1136/jim-2022-002339 |
_version_ | 1784768896733020160 |
---|---|
author | Liu, Chang Cheng, Binglu Zhao, Gang Yuan, Hengjie |
author_facet | Liu, Chang Cheng, Binglu Zhao, Gang Yuan, Hengjie |
author_sort | Liu, Chang |
collection | PubMed |
description | This study aimed to explore the clinical adverse effects of anthracyclines on patients undergoing chemotherapy after breast cancer surgery. A total of 118 patients who received anthracycline chemotherapy after breast cancer surgery were selected as the research object, and the changes of echocardiogram, ECG, myocardial enzymes and blood biochemical indices before, during and after chemotherapy were studied. SPSS V.20 was used to conduct statistical analysis. The differences in heart rate, ST-segment abnormalities, creatine kinase, lactate dehydrogenase, hemoglobin, albumin, triglycerides and high-density lipoprotein were statistically significant. Heart rate and triglycerides increased significantly in the early stage of chemotherapy; ST-segment abnormality increased during the entire chemotherapy period; creatine kinase and lactate dehydrogenase increased significantly in the late stage of chemotherapy; hemoglobin and albumin decreased in the early stage of chemotherapy. The magnitude is large; high-density lipoprotein decreases throughout the chemotherapy period. In anthracycline chemotherapy regimens, bone marrow suppression and dyslipidemia occur in the early stage of chemotherapy, and the risk of cardiotoxicity is higher in the late stage of chemotherapy. |
format | Online Article Text |
id | pubmed-9380491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-93804912022-08-30 Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy Liu, Chang Cheng, Binglu Zhao, Gang Yuan, Hengjie J Investig Med Original Research This study aimed to explore the clinical adverse effects of anthracyclines on patients undergoing chemotherapy after breast cancer surgery. A total of 118 patients who received anthracycline chemotherapy after breast cancer surgery were selected as the research object, and the changes of echocardiogram, ECG, myocardial enzymes and blood biochemical indices before, during and after chemotherapy were studied. SPSS V.20 was used to conduct statistical analysis. The differences in heart rate, ST-segment abnormalities, creatine kinase, lactate dehydrogenase, hemoglobin, albumin, triglycerides and high-density lipoprotein were statistically significant. Heart rate and triglycerides increased significantly in the early stage of chemotherapy; ST-segment abnormality increased during the entire chemotherapy period; creatine kinase and lactate dehydrogenase increased significantly in the late stage of chemotherapy; hemoglobin and albumin decreased in the early stage of chemotherapy. The magnitude is large; high-density lipoprotein decreases throughout the chemotherapy period. In anthracycline chemotherapy regimens, bone marrow suppression and dyslipidemia occur in the early stage of chemotherapy, and the risk of cardiotoxicity is higher in the late stage of chemotherapy. BMJ Publishing Group 2022-08 2022-04-04 /pmc/articles/PMC9380491/ /pubmed/35379700 http://dx.doi.org/10.1136/jim-2022-002339 Text en © American Federation for Medical Research 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Liu, Chang Cheng, Binglu Zhao, Gang Yuan, Hengjie Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy |
title | Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy |
title_full | Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy |
title_fullStr | Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy |
title_full_unstemmed | Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy |
title_short | Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy |
title_sort | process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380491/ https://www.ncbi.nlm.nih.gov/pubmed/35379700 http://dx.doi.org/10.1136/jim-2022-002339 |
work_keys_str_mv | AT liuchang processanalysisofanthracyclineadversereactionsinbreastcancerpatientswithpostoperativechemotherapy AT chengbinglu processanalysisofanthracyclineadversereactionsinbreastcancerpatientswithpostoperativechemotherapy AT zhaogang processanalysisofanthracyclineadversereactionsinbreastcancerpatientswithpostoperativechemotherapy AT yuanhengjie processanalysisofanthracyclineadversereactionsinbreastcancerpatientswithpostoperativechemotherapy |